Price as at:
Fundamentals last refreshed: 13 Nov 2026
CSL Limited is an Australian biotechnology company specializing in rare and serious diseases, influenza vaccines, and treatments for iron deficiency and nephrology. It comprises three main segments: CSL Behring, which focuses on plasma products, gene therapies, and recombinants; CSL Seqirus, dedicated to influenza vaccines and pandemic services; and CSL Vifor, which targets iron deficiency and nephrology therapeutics. The company also has a plasma collection network, CSL Plasma, with over 325 centers across the United States, Europe, and China.
Operating globally, with a presence in Australia, the United States, Germany, the UK, Switzerland, and China, CSL Limited offers products like Respreeza, Zemaira, HAEGARDA, KCENTRA, and Hepatitis B immunoglobulins, among others. Founded in 1991, the company has grown to employ over 32,000 people worldwide.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Overview
Key facts
- Ticker
- CSL
- Exchange
- AU
- ISIN
- AU000000CSL8
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Currency
- AUD
- Price
- A$202.92
- Previous close
- A$204.54
- Day change
- -A$1.62 (-0.79%)
- Market cap
- 97.4B
- 52W low
- A$88.84
- 52W high
- A$205.48
Price and trend
Last price: A$202.92
- Price
- A$202.92
- 52W range
- A$88.84 – A$205.48
- 50-day SMA
- A$186.24
- 200-day SMA
- A$145.12
- Price vs 50D SMA
- 8.96%
- Price vs 200D SMA
- 39.83%
Valuation
- P/E
- 0.00
- PEG
- 1.82
- EPS
- -7.90
- Dividend yield
- 1.43%
- Beta
- 0.08
Profitability and growth
- Revenue growth
- 5.50%
- Revenue TTM
- 15.8B
- Profit margin
- -16.33%
Analyst view
Comparison uses the last price shown; targets are analyst estimates.
- Price
- A$202.92
- Target price
- A$198.10
- Target vs last price
- -2.38% from last price
*This content is aimed to provide general information only, and does not take your personal objectives, financial situation or needs into account.
CSL Limited (ASX: CSL) Fundamentals
